SBIR/STTR Research Award

PERCUTANEOUS TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE WITH IMPLANTATION OF SERIAL, BALLOON-EXPANDABLE, PACLITAXEL-ELUTING RESORBABLE SCAFFOLDS (the Efemoral Device)

Award identifier 0fe3dee9961bf93774cd60d8f9516a59f499347e0354228f323ffd76d2d5689dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$150,000

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Efemoral Medical, LLC
Proposal award date
2019-09-26
Contract end date
2020-09-25
UEI
TLM3ATBMLL53
Solicitation number
PA18-574
Topic code
NHLBI

Research abstract

Project Summary Abstract TITLEPERCUTANEOUS TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE WITH IMPLANTATION OF SERIALBALLOON EXPANDABLEPACLITAXEL ELUTING RESORBABLE SCAFFOLDSthe Efemoral DeviceAbstract Peripheral Arterial Occlusive DiseasePAODalso known as Peripheral Vascular Diseasepoor circulationorhardening of the arteriesis a worldwide plagueSymptomatic PAOD affects approximatelyof the population over the age ofandof the population over the age ofLeft untreatedit can lead to severe disability and extremity amputationLimb loss in the aging American population has reached epidemic proportionsthe annual cost of managing the approximatelymillion citizens currently living with extremity amputations has been estimated at $billionCurrentlythe treatment of choice for restoring patency to stenotic or occluded arteries in symptomatic patients with PAOD is percutaneous balloon angioplasty followed by implantation of permanent metal stentsUnfortunatelytheir effectiveness remains limited as up toof conventional endovascular procedures will be complicated by arterial restenosis and recurrence within the first yearThis research proposal describes the development of novelballoon expandableresorbablepaclitaxel eluting scaffold designed to provide more effective and durable endovascular treatment of symptomatic PAODIts Specific Aim is to conduct the first long termcontrolledpre clinical animal study using the device Project Narrative TITLEPERCUTANEOUS TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE WITH IMPLANTATION OF SERIALBALLOON EXPANDABLEPACLITAXEL ELUTING RESORBABLE SCAFFOLDSthe Efemoral DeviceThe pathological degeneration of arteries known asatherosclerosisis responsible for one third of all human mortalityIt represents a tremendous current and future health burden accountable for andgtmillion projected annual deaths by the yearAtherosclerosis involving lower extremity arteriesknown asperipheral arterial occlusive diseasePAODaffectsof the population overyears oldLeft untreatedsymptomatic patients can sustain severe disabilitylimb loss and or deathThe standard of care for patients with symptomatic PAOD is percutaneous peripheral interventionPPIincluding the techniques of balloon angioplastydrug coated balloon angioplastypercutaneous atherectomyand bare and drug eluting self expanding stentingUnfortunatelythe effectiveness and durability of available devices is limited as up toof conventional endovascular procedures will be complicated by arterial restenosis and recurrence within the first yearThis research proposal describes the development of novelserialballoon expandableresorbablepaclitaxeleluting scaffold designed to provide more immediately effective and durable endovascular treatment of symptomatic femoropopliteal occlusive diseaseUnlike most peripheral intravascular devices that are simply adaptations andscale upsof coronary devicesthe Efemoral scaffold system is specifically designed for the unique environment of the peripheral vasculatureIts design exploits known principles of vascular biology including thata rigid device that is deployed via balloon expansion represents the optimal design of an intravascular stent given its transient effect on the arterial wall and relative ease of precise implantationa longrigid device cannot be safely implanted in an artery that bends and twists with skeletal motionlong arteries that bend and twist could be effectively treated with multipleshort stents that allow the interveningnon stented arterial segments to move unencumberedthe lengthnumber and spacing of the stent segments could be determined by the known bending characteristics of the target arteriesandarteries need only be scaffolded transientlylate dissolution of the stent will have no effect on the effectiveness of treatmentThis SBIR proposal describes the pre clinical development of the Efemoral devicea serialballoonexpandableresorbablepaclitaxel eluting scaffold designed to provide more effective and durable endovascular treatment of symptomatic PAODIts Specific Aim is to conduct the firstlong term animal study using this novel deviceEfemoral MedicalIncwas co founded by a vascular surgeon and serial biotechnical entrepreneur with over fifty years of collective experience in vascular interventionmedical device development and early stage start up initiativesThe partnership and team brings a wealth of domain specific knowledge and professional contacts for the application of new technologies for vascular diseaseThe company has already garnered private funding and made significant progress is reaching initial developmental milestonesThis application seeks to extend these early observations through the conduct of a large scalelong termcontrolled pre clinical study with the hypothesis that the vascular response to the Efemoral Device will be superior to the current standard of care

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2019–2022). Reported award amounts total $2,126,052. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.